| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | -65,7 € | -3.0% | -63,8 € | +96.3% | -1,7 k € | -2893.3% | -57,0 € | -3.8% | -54,9 € | -0.7% | -54,5 € | -104.8% | 1,1 k € | +7.6% | 1,1 k € | -52.5% | 2,2 k € | +13.9% | 2,0 k € | +120.1% | 893,3 € | -81.1% | 4,7 k € | |
| EBITDA | -719,5 € | -2.5% | -701,6 € | +69.9% | -2,3 k € | -266.5% | -636,3 € | +14.3% | -742,6 € | +28.7% | -1,0 k € | -817.5% | 145,2 € | +44.3% | 100,6 € | -90.1% | 1,0 k € | -33.2% | 1,5 k € | +4549.3% | 32,8 € | -99.2% | 3,9 k € | |
| Operating profit | -719,5 € | -2.5% | -701,6 € | +69.9% | -2,3 k € | -266.5% | -636,3 € | +14.3% | -742,6 € | +28.7% | -1,0 k € | -817.5% | 145,2 € | +44.3% | 100,6 € | -90.1% | 1,0 k € | -33.2% | 1,5 k € | +4549.3% | 32,8 € | -99.2% | 3,9 k € | |
| Profit/loss | -33,2 k € | -2671.8% | 1,3 k € | +114.5% | -8,9 k € | +71.1% | -30,9 k € | +18.7% | -38,0 k € | +90.0% | -379,0 k € | -15.6% | -327,9 k € | -893.2% | 41,3 k € | +158.2% | -71,0 k € | -8824.3% | 813,9 € | +1374.0% | 55,2 € | -98.2% | 3,1 k € | |
| Equity | 109,7 k € | -23.2% | 142,9 k € | +0.9% | 141,6 k € | -5.9% | 150,5 k € | -17.0% | 181,4 k € | -17.3% | 219,3 k € | -63.3% | 598,4 k € | -35.4% | 926,2 k € | +4.7% | 884,9 k € | -18.7% | 1,1 M € | +20.2% | 904,7 k € | +87.5% | 482,6 k € | |
| Total assets | 110,2 k € | -23.1% | 143,3 k € | -0.2% | 143,5 k € | -4.7% | 150,6 k € | -17.0% | 181,5 k € | -17.3% | 219,3 k € | -63.4% | 598,5 k € | -35.4% | 926,3 k € | +4.6% | 885,5 k € | -18.8% | 1,1 M € | +8.7% | 1,0 M € | +89.1% | 530,6 k € | |
| Cash | 3,6 k € | -8.4% | 3,9 k € | -81.5% | 21,3 k € | -3.9% | 22,2 k € | -3.1% | 22,9 k € | -3.0% | 23,6 k € | +592.1% | 3,4 k € | -21.5% | 4,3 k € | -82.8% | 25,2 k € | -15.6% | 29,8 k € | +8.8% | 27,4 k € | -40.8% | 46,3 k € | |
| Debts | 509,7 € | +31.6% | 387,3 € | -80.2% | 2,0 k € | +1678.2% | 110,0 € | 0.0% | 110,0 € | — | 188,5 € | +485.2% | 32,2 € | -94.8% | 622,3 € | +4.9% | 593,3 € | -99.4% | 98,6 k € | +105.5% | 48,0 k € | |||
Private limited company · Sint-Martens-Latem · incorporated on 09/09/2013
Private limited company loss-making in the latest fiscal year. Cash position declining (-8.4%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
EPM Pharma Invest is a Private limited company incorporated in 2013. Its registered office is in Sint-Martens-Latem.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette